Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$3.65
$0.09(3.04%)
At close: 4:00 PM EDT
$3.65
$0.09(3.04%)
Day’s Range― - ―
52-Week Range$1.77 - $4.05
Previous CloseN/A
Volume1.06M
Average Volume (3M)825.40K
Market Cap
$1.15B
Enterprise Value$1.25B
Total Cash (Recent Filing)$296.11M
Total Debt (Recent Filing)$538.95M
Price to Earnings (P/E)63.9
Beta1.13
Next Earnings
Nov 10, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding107,181,200
10 Day Avg. Volume857,723
30 Day Avg. Volume825,396
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit1.80
Enterprise Value/Ebitda7.29
Forecast
1Y Price Target
$4.21Price Target Upside15.37% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.3
Revenue Forecast (FY)$799.58M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Manageable LeverageSolid and improving operating cash flow and free cash flow provide internal funding for product investment and reduce reliance on external capital. Combined with debt below equity and positive shareholder equity, this supports financial resilience through the business model transition.
Rapid Pharma Direct Growth And Raised GuidancePharma Direct is becoming a meaningful growth engine, with rapid quarterly expansion and management expecting more than 70% full-year growth. Raised revenue and EBITDA guidance indicates execution is translating into a stronger, more diversified earnings base.
Subscription Momentum And Platform DiversificationSubscription growth and the Companion launch broaden GoodRx beyond individual prescription transactions toward recurring, higher-lifetime-value relationships. This diversification can make revenue more durable while increasing engagement across medication savings, online care, and related benefits.
Bears Say
Sharp Revenue Decline And Thin ProfitabilityThe sharp TTM revenue contraction shows that the legacy business has faced meaningful top-line pressure, while thin profitability limits earnings protection. Recent losses and modest current income indicate the newer growth engines must scale substantially to create durable bottom-line expansion.
Declining Consumers And Moderating Prescription RevenueLower monthly active consumers and moderating prescription-transaction revenue weaken the scale of GoodRx’s traditional marketplace engine. Even if migration to subscriptions is intentional, reduced activity can pressure transaction economics and requires newer offerings to replace lost volume.
Uncertainty Around Margins During Mix ShiftThe shift toward subscriptions and other newer offerings may alter cost-to-serve and gross-margin economics. Higher cost of revenue alongside absent updated margin guidance makes it harder to establish how much of the reported growth will convert into sustainable operating profitability.
GoodRx Holdings News
GDRX FAQ
What was GoodRx Holdings’s price range in the past 12 months?
GoodRx Holdings lowest stock price was $1.77 and its highest was $4.05 in the past 12 months.
What is GoodRx Holdings’s market cap?
GoodRx Holdings’s market cap is $1.15B.
When is GoodRx Holdings’s upcoming earnings report date?
GoodRx Holdings’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.
How were GoodRx Holdings’s earnings last quarter?
GoodRx Holdings released its earnings results on Aug 05, 2026. The company reported $0.08 earnings per share for the quarter.
Is GoodRx Holdings overvalued?
According to Wall Street analysts GoodRx Holdings’s price is currently Undervalued.
Does GoodRx Holdings pay dividends?
GoodRx Holdings does not currently pay dividends.
What is GoodRx Holdings’s EPS estimate?
GoodRx Holdings’s EPS estimate is 0.08.
How many shares outstanding does GoodRx Holdings have?
GoodRx Holdings has 107,181,200 shares outstanding.
What happened to GoodRx Holdings’s price movement after its last earnings report?
GoodRx Holdings reported an EPS of $0.08 in its last earnings report. Following the earnings report the stock price went up 13.761%.
Which hedge fund is a major shareholder of GoodRx Holdings?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.21 (15.37% Upside)
$4.21 (15.37% Upside)
Blogger Sentiment
Neutral
GDRX Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 611.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.01%
12-Months-Change
Fundamentals
Return on Equity
2.61%
Trailing 12-Months
Asset Growth
77.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GoodRx Holdings
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
GDRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution and visible, high-growth revenue engines (Pharma Direct and subscriptions) with meaningful beats and raised full-year guidance. These positives were tempered by declines in monthly active consumers, moderation of traditional prescription transaction revenue and limited disclosure of prescription-level KPIs during a strategic transition. Management framed the shifts as intentional investments in more durable, higher-LTV revenue streams and signaled confidence in sustained growth, while acknowledging some short-term metric and disclosure trade-offs.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$4.21
▲(15.37% Upside)
Technical Analysis
Ownership Overview
12.95% Insiders
9.86% Mutual Funds
0.13% Other Institutional Investors
67.07% Public Companies and
Individual Investors